MOLBIO DIAGNOSTICS LTD – Q1 FY27 CONCALL HIGHLIGHTS
#Q1FY27
Q1FY27 Performance
- Consolidated revenue from operations stood at ₹408 Cr.
- Sold 164 devices and 62.4 lakh test kits during Q1.
- Export revenue was ₹67 Cr, contributing 16% of total revenue.
- EBITDA stood at ₹104 Cr, with 25% EBITDA margin; PAT was ₹52.7 Cr.
- Management targets FY27 revenue growth of around 25% and EBITDA margin of 24–25%.
TruNat Platform
- 12,500 machines installed across 90+ countries, with 43 assays covering 30 diseases.
- Platform has conducted 5–6 Mn+ tests historically and generates recurring revenue through proprietary consumables.
- Around 75% of revenue currently comes from test kits.
- Early installations from 2017–18 are still running, with no device replacement cycle seen so far.
- TruNat is a closed proprietary system; third-party consumables cannot be used.
- Same machine can test multiple diseases; consumables change according to the test.
TB Opportunity
- India has around 25,000–30,000 TB diagnostic centres, while TruNat has reached only around 8,000–9,000.
- Remaining centres largely use traditional microscopy, creating a long runway for molecular diagnostic conversion.
- TruNat is one of only 2 WHO-endorsed molecular TB technologies, and the only one that is battery-operated and deployable at point-of-care.
- Newly completed government TB tender provides a 2-year contract.
- Management sees significant further opportunity in both India and international TB programs.
HPV Opportunity
- TruNat HPV underwent extensive validation led by AIIMS with support from WHO/Gates-linked agencies and was found to meet international criteria.
- Government of India has recommended rollout under the national program and found the test cost-effective.
- WHO prequalification application is also being pursued for international expansion.
- Management expects greater clarity on deployment and volumes next quarter.
Exports & Global Expansion
- Export business began around 2023 and is still in the network-building/ramp-up phase.
- Distributor network spans 90 countries, with registrations continuing across markets.
- Europe is opening through stringent IVDR/IBDR certifications, including TruNat CT-NG for chlamydia and gonorrhea.
- Management expects exports to become an important growth driver over the coming years.
- Developed-market expansion includes Europe and the US through TruNat, Prognosis and OptraScan.
Manufacturing & CapEx
- Test-kit capacity utilization is around 58%, while device capacity utilization is around 42%.
- Of the ₹200 Cr IPO proceeds, around ₹72 Cr is earmarked for automation.
- Automation should improve efficiency and enable the company to potentially double revenue from FY26 levels without major capacity expansion.
- Around ₹105 Cr will be invested in an integrated R&D centre in Bangalore.
- No major additional CapEx is currently envisaged.
R&D & Innovation
- R&D spending is maintained at around 5–6% of revenue.
- Company has 153+ scientists and 207+ patents.
- Bulk of future R&D investment will shift toward new diagnostic platforms, rather than only adding assays to TruNat.
- Focus includes both infectious and non-communicable diseases.
- Management estimates the addressable opportunity for future NCD point-of-care platforms could be 10x+ the current molecular-testing opportunity.
Prognosis
- Prognosis contributed around ₹11 Cr revenue in Q1.
- FY26 revenue was ₹154 Cr, with around ₹12 Cr PAT.
- Management expects FY27 EBITDA margin to remain around 19%, broadly similar to FY26.
- Ultra-portable X-ray products can complement TruNat for TB screening + confirmatory testing.
- Veterinary applications, particularly companion animals, are another potential growth avenue.
OptraScan
- OptraScan received US FDA clearance in July 2026 for its end-to-end digital pathology workflow covering hardware, software and AI.
- US represents around 60% of the global pathology market; discussions with large US laboratory/hospital chains are underway.
- India already has around 35–40 installations.
- OptraScan received ~$30 Mn fresh capital and is fully funded for the next 2–3 years.
- FY27 is expected to remain muted; meaningful contribution is expected from FY28–FY29 onward.
Business Outlook
- Management cautions against judging performance quarter-to-quarter as public-health business can be non-linear.
- Growth will be driven by higher machine installations, recurring kit consumption, new assays, exports and new platforms.
- Existing TB opportunity remains substantial, while HPV, hepatitis and international markets provide additional growth avenues.
KEY TAKEAWAY
- 25% growth target + 75% recurring kit revenue + strong global runway.
1September 9, 2026 600
